CODX · Co-Diagnostics, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Because certain elements of management's plans to mitigate the conditions that raised substantial doubt about the Company's ability to continue as a going concern are outside of the Company's control, including the ability to raise capital through equity or other financings, those elements cannot be considered probable according to ASC 205-40, and therefore cannot be considered in the evaluation of mitigating factors. As a result, management has concluded that substantial doubt exists about the Company's ability to continue as a going concern for 12 months from the date these condensed consolidated financial statements are issued.”View the 10-Q filed Aug 13, 2026
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 13, 2026TL;DR. Co-Diagnostics reported a $6.3M net loss on $166K of Q2 revenue while submitting its FDA 510(k) and CLIA waiver application for the Co-Dx PCR Flu A/B & RSV test, advancing TB clinical work in India, and completing a proof-of-concept Ebola assay. Cash fell to $3.6M from $11.9M at year-end 2025, prompting the company to flag potential dilutive financings to support commercialization.
- + Submitted 510(k) and CLIA waiver application for the Flu A/B & RSV test after completing clinical studies with 1,400+ patients and 27 analytical studies. new
- + Reduced net loss to $6.3M from $7.7M and cut operating expenses to $6.3M from $8.2M year-over-year. new
- + Completed proof-of-concept Ebola assay on the Co-Dx PCR Pro and supplied Bundibugyo test kits for evaluation in India. new
- − Revenue remains minimal at $166K, with gross profit declining to $121K from $131K year-over-year. new
- − Cash and cash equivalents declined to $3.6M from $11.9M at year-end 2025, and management flagged potential dilutive financings ahead. new
- − Management expects continued operating losses in the near term with commercialization still pending. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | 5.8M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CODX
this stock
Co-Diagnostics, Inc.
|
$6.82M | — | -84.1% | — | 4.9% |
|
ABT
Abbott Laboratories
|
$174.90B | -21.1% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -10.2% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -21.6% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -54.2% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CODX | -2.7% | -10.1% | -25.7% | -13.7% | -78.9% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -2.1% | -10.2% | -37.9% | -13.1% | -90.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.